Deal puts liver-targeted mRNA therapies on horizon for BioNTech, Genevant

A pair of deals between BioNTech AG (Mainz, Germany) and Genevant Sciences will propel mRNA-based therapeutics for rare diseases into the clinic as soon as 2020 and allow BioNTech to harness the liver's robust protein production capacity. Genevant,

Read the full 383 word article

User Sign In